<DOC>
	<DOCNO>NCT02047149</DOCNO>
	<brief_summary>Prospective nonrandomized phase I study The purpose study determine safety efficacy zileuton add dasatinib patient chronic myelogenous leukemia ( CML ) .</brief_summary>
	<brief_title>Evaluating Safety Zileuton ( Zyflo® ) Combination With Dasatinib ( Sprycel® ) Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>The standard treatment chronic myelogenous leukemia therapy tyrosine kinase inhibitor ( TKIs ) . This treatment diminish amount disease low level sensitive specialize technique measure ; , however , provide cure . Dr. Shaoguang Li colleague University Massachusetts publish unique discovery arachidonate 5-lipoxygenase ( 5-LO ) gene ( Alox5 ) critical regulator LSCs BCR-ABL-induced CML ( Chen Y et al . Loss Alox5 gene impairs leukemia stem cell prevent chronic myeloid leukemia . Nature Genetics 41:783-792 , 2009 ) . In absence Alox5 , BCR-ABL fail induce CML preclinical study . While deficiency Alox5 effect normal hematopoiesis , impairment LSCs function differentiation cell division CML LSCs observe . This defect lead depletion LSCs failure CML development . Treatment 5-LO inhibitor ( zileuton ) also impaired function LSCs prolong survival . These result demonstrate specific target gene find cancer stem cell inhibition completely inhibit function stem cell . These finding provide excite opportunity develop first anti-cancer stem cell therapy treat CML . Patients respond tolerate two TKIs consider study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Zileuton</mesh_term>
	<criteria>Target Population : 1 . Patients CML know inadequate response ( appropriate CML status ) TKIs know resistance consider study Patients resistant respond adequately dasatinib first line therapy , able eligible receive effective second line treatment consider participation study . Age &gt; 18 year ECOG performance status ≤ 2 Total bilirubin &lt; 2.0 time institutional Upper Limit Normal ( ULN ) Hepatic enzyme ( AST , ALT ) ≤ 1.5 time institutional ULN Serum Na , K+ , Mg2+ , Phosphate Ca2+ &gt; = Lower Limit Normal ( LLN ) Serum Creatinine &lt; 2.3 mg/dL PT , PTT Grade 01 3 ) Ability take oral medication 4 ) Concomitant Medications Patient agree discontinue St. Johns Wort receive dasatinib therapy 5 ) Age Sex Women childbearing potential men father potential must use adequate method contraception avoid pregnancy throughout study minimize risk pregnancy 1 . Sex Reproductive Status Women childbearing potential men father potential unable unwilling use adequate method contraception avoid pregnancy throughout study minimize risk pregnancy 2 . Target Population Patients intolerant dasatinib . 3 . Medical History Concurrent Diseases History active malignancy past 5 year exception nonmetastatic treated skin cancer ( e.g . basal squamous cell carcinoma ) stage 0 cervical carcinoma Patients know HIVpositive Patients active , uncontrolled infection Concurrent medical condition may increase risk toxicity , include : Pleural pericardial effusion grade Cardiac Conditions : Uncontrolled angina , congestive heart failure MI within ( 6 month ) Diagnosed congenital long QT syndrome Any history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) Prolonged QTc interval preentry electrocardiogram ( &gt; 450 msec ) Severe cardiac dysfunction ( NYHA classification IIIIV ) Severe pulmonary disease History significant bleeding disorder unrelated cancer 4 . Physical Laboratory Test Findings Hepatic dysfunction ( serum bilirubin ≥ 2 x ULN , and/or ALT ≥ 3 x ULN , and/or AST ≥ 3 x ULN ) Renal dysfunction ( creatinine ≥ 200 μmol/l 2.3 mg/dl ) Subjects hypokalemia hypomagnesemia correct prior dasatinib administration 5 . Allergies Adverse Drug Reactions Patients know allergic reaction intolerance either dasatinib zileuton 6 . Prohibited Treatments and/or Therapies Category I drug generally accept risk cause Torsades de Pointes include : quinidine , procainamide , disopyramide amiodarone , sotalol , ibutilide , dofetilide erythromycin , clarithromycin chlorpromazine , haloperidol , mesoridazine , thioridazine , pimozide cisapride , bepridil , droperidol , methadone , arsenic , chloroquine , domperidone , halofantrine , levomethadyl , pentamidine , sparfloxacin , lidoflazine . Patients require anticoagulation Coumadin 7 . Other Exclusion Criteria Prisoners subject involuntarily incarcerate . Subjects compulsorily detain treatment either psychiatric physical ( e.g . infectious disease ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myelogenous Leukemia</keyword>
</DOC>